Tech Company Financing Transactions

KalVista Pharmaceuticals Funding Round

KalVista Pharmaceuticals, based in Cambridge, secured $33 million from RA Capital, Longwood Fund and Novo Ventures.

Transaction Overview

Announced On
7/23/2015
Transaction Type
Venture Equity
Amount
$33,000,000
Round
Series B
Investors

RA Capital (Lead Investor) (Rajeev Shah)

Longwood Fund (Rich Aldrich)

Novo Ventures

SV Health Investors

Venrock (Bong Koh)

Proceeds Purpose
KalVista will use the funds to advance its proprietary portfolio of plasma kallikrein inhibitors for treating diabetic macular edema (DME) and hereditary angioedema (HAE).

Company Information

Company Status
Private & Independent
Industry
Biopharmaceutical
Mailing Address
55 Cambridge Pkwy. 901E
Cambridge, MA 02142
USA
Email Address
Overview
KalVista is a research-led pharmaceutical company focused on the discovery, development and commercialization of small molecule serine protease inhibitors as new treatments for diseases with significant unmet need.
Profile
KalVista Pharmaceuticals LinkedIn Company Profile
Social Media
KalVista Pharmaceuticals Company Twitter Account
Company News
KalVista Pharmaceuticals News
Facebook
KalVista Pharmaceuticals on Facebook
YouTube
KalVista Pharmaceuticals on YouTube

Management Team

Title
Name
Email & Social
Chief Executive Officer
Andrew Crockett
  Andrew Crockett LinkedIn Profile  Andrew Crockett Twitter Account  Andrew Crockett News  Andrew Crockett on Facebook
Chief Financial Officer
Benjamin Palleiko
  Benjamin Palleiko LinkedIn Profile  Benjamin Palleiko Twitter Account  Benjamin Palleiko News  Benjamin Palleiko on Facebook
Chief Medical Officer
Andreas Maetzel
  Andreas Maetzel LinkedIn Profile  Andreas Maetzel Twitter Account  Andreas Maetzel News  Andreas Maetzel on Facebook
Chief Scientific Officer
Edward Feener
  Edward Feener LinkedIn Profile  Edward Feener Twitter Account  Edward Feener News  Edward Feener on Facebook
VP - Bus. Development
Michael Smith
  Michael Smith LinkedIn Profile  Michael Smith Twitter Account  Michael Smith News  Michael Smith on Facebook
VP - Bus. Development
Christopher Yea
  Christopher Yea LinkedIn Profile  Christopher Yea Twitter Account  Christopher Yea News  Christopher Yea on Facebook


 

 

Browse more venture capital transactions:

Prev: 7/23/2015: Zimplistic venture capital transaction
Next: 7/23/2015: BlueCava venture capital transaction

 

Share this article

 


About Database of VC Transactions

We do our best to report on every notable VC transaction. VC investment data records reported here are sourced from company press releases and news coverage. The information comes to us via our partnership with VentureDeal.com, an affiliated venture.

 


Additional Resources for Entrepreneurs

Lists of Venture Capital and Private Equity Firms

Franchise Opportunities

Contributors

Business Glossary